One of the many issues that needs to be negotiated in the wake of British prime minister Theresa May’s triggering of Article 50 is the location of the European Medicines Agency (EMA).
Depression is the leading cause of disability worldwide, affecting over 300m people – but less than half of them are getting effective treatment.
Drug development is a lengthy, complicated and costly process, with a high rate of attrition.
In developed markets, especially the US, pharmaceutical companies are facing a period of uncertainty, with pricing and reimbursements concerns causing significant barriers to revenue potential.
As the world’s first human head transplant rapidly approaches, it’s time to face the implications this could have for the future of surgery and pharma therapy.